Format

Send to

Choose Destination
Antimicrob Agents Chemother. 2020 Jan 27;64(2). pii: e02102-19. doi: 10.1128/AAC.02102-19. Print 2020 Jan 27.

Ex Vivo Urinary Bactericidal Activity and Urinary Pharmacodynamics of Fosfomycin after Two Repeated Dosing Regimens of Oral Fosfomycin Tromethamine in Healthy Adult Subjects.

Author information

1
College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois, USA.
2
College of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA.
3
JMI Laboratories, North Liberty, Iowa, USA.
4
Harvard TH Chan School of Public Health, Boston, Massachusetts, USA.
5
College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois, USA kar@uic.edu.

Abstract

The ex vivo bactericidal activity and pharmacodynamics of fosfomycin in urine were evaluated in 18 healthy subjects. Subjects received 3 g every other day (QOD) for 3 doses and then every day (QD) for 7 doses or vice versa. Serial urine samples were collected before and up to 24 h after dosing on days 1 and 5. Eight bacterial strains with various genotypic and phenotypic susceptibilities to fosfomycin were used for all experiments (5 Escherichia coli, 2 Klebsiella pneumoniae, and 1 Proteus mirabilis). MICs were performed via agar dilution. Urinary bactericidal titers (UBTs) were performed via modified Schlichter test using participant's drug-free urine as the diluent. Urinary time-kill analyses were performed on pooled 24-h urine aliquots from days 1 and 5. All experiments were performed in triplicate with and without the addition of 25 mg/liter of glucose-6-phosphate (G6P). Mean 24-h urine concentrations of fosfomycin ranged from 324.7 to 434.6 mg/liter regardless of study day or dosing regimen. The urinary antibacterial activity of fosfomycin was also similar across study days and dosing regimens. UBT values did not correlate with MICs determined in the presence of G6P. Fosfomycin was reliably bactericidal in urine only against the 5 E. coli strains, regardless of genotype or MIC value. Together, these data do not support the use of oral fosfomycin tromethamine for pathogens other than E. coli or at a dosing frequency higher than QOD. Fosfomycin MICs determined in the presence of G6P may not accurately reflect the in vivo activity given the lack of G6P in human urine. (This study has been registered at ClinicalTrials.gov under identifier NCT02570074.).

KEYWORDS:

fosfomycin; pharmacodynamics; urinary bactericidal titers; urinary tract infection; urine

PMID:
31767717
PMCID:
PMC6985713
[Available on 2020-07-27]
DOI:
10.1128/AAC.02102-19

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center